SCHEMBL533215

SCHEMBL533215

O=S(=O)(Cl)c1c(Cl)cc(C(F)(F)F)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 3/20 0.39
MAPT P10636 2/20 0.39
TSHR P16473 2/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
HIF1A Q16665 1/20 0.38
TXNRD1 Q16881 1/20 0.38
TXNRD3 Q86VQ6 1/20 0.38
TXNRD2 Q9NNW7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PFKFB4 Q16877 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 2/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KMT2A Q03164 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4636558 0.81 MRGPRX4 (0.40) MCL1ALDH1A1LMNAHTTMAPT
SCHEMBL20560677 0.78 TRPV4 (0.40) MCL1ALDH1A1LMNAHTTMAPT
SCHEMBL6896643 0.78 ALDH1A1 (0.41) MCL1ALDH1A1LMNAHTTMAPT
SCHEMBL23351953 0.76 PDE2A (0.42) MCL1ALDH1A1LMNAHTTMAPT
SCHEMBL185181 0.75 ACLY (0.41) ALDH1A1LMNAHTTMAPTTSHR
SCHEMBL6114601 0.75 KMT2A (0.35) MCL1ALDH1A1LMNAHTTMAPT
SCHEMBL4476920 0.75 TRPV4 (0.35) KMT2A
SCHEMBL181647 0.74 ALDH1A1 (0.43) ALDH1A1TSHRCYP3A4HPGDKMT2A
SCHEMBL29907293 0.74 TRPV4 (0.53) MCL1ALDH1A1TSHRL3MBTL1KMT2A
SCHEMBL66378 0.74 TRPV4 (0.53) MCL1ALDH1A1TSHRL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof Maxymune Therapeutics, Inc. (US) 2025-09-30 US disclosed
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US disclosed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
EP-3790858-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY Glucox Biotech AB (SE) 2021-03-17 EP disclosed
WO-2019215291-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2019-11-14 WO disclosed
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 EP disclosed
WO-2004043366-A2 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2004-05-27 WO disclosed
EP-1385495-A2 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US disclosed
WO-2003070244-A1 ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES ABBOTT LABORATORIES (US) 2003-08-28 WO disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 WO disclosed
WO-2002089740-A2 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR MCL1 4766/4885ALDH1A1 4452/4885LMNA 4591/4885
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity NOX4, NOX1, NOX5 MCL1 2576/4885ALDH1A1 493/4885LMNA 4423/4885
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 MCL1 3192/4885ALDH1A1 2745/4885LMNA 4750/4885
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 MCL1 2735/4885ALDH1A1 473/4885LMNA 4636/4885
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 MCL1 2735/4885ALDH1A1 473/4885LMNA 4636/4885
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R MCL1 4650/4885ALDH1A1 2373/4885LMNA 3981/4885
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof SLC43A1, SLC7A1, SLC1A5 MCL1 3192/4885ALDH1A1 2745/4885LMNA 4750/4885
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 MCL1 3192/4885ALDH1A1 2745/4885LMNA 4750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.